Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19

Background: Tocilizumab is used in severe COVID-19 yet has significant rates of treatment failure. Objectives: This retrospective study aimed to identify early predictors of the response to tocilizumab therapy. Methods: Biochemical and clinical characteristics of adult patients who received tocilizu...

Descripción completa

Detalles Bibliográficos
Autores principales: Singla, Karan, Puri, Goverdhan D, Guha Niyogi, Subhrashis, Mahajan, Varun, Kajal, Kamal, Bhalla, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Anesthesiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509663/
https://www.ncbi.nlm.nih.gov/pubmed/36176874
http://dx.doi.org/10.7759/cureus.28428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509663/
https://www.ncbi.nlm.nih.gov/pubmed/36176874
http://dx.doi.org/10.7759/cureus.28428

Ejemplares similares